natgillin/translations-raw huggingface dataset:
the assembling of the profiles (2) is finished by using another terminal fixing element (10) and by pressure fitting the said terminal fixing element into the groove (3) of the settlement profile (1). 
- < sastavljanje profila (2) se završava pomoću drugog krajnjeg elementa za pričvršćivanje (10) i postavljanja pritiskom navedenog krajnjeg elementa za pričvršćivanje u utor (3) ugradbenog profila (1).
is —CH3. The compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
wherein: Ar is selected from the group consisting of phenyl and thiophen-yl; 
Ar je odabran iz skupine koju čine: 4-(1H-imidazol-1-il)fenil,
a base in an amount to adjust the pH to 6 to 8, preferably a pH of 7.3, 
baza u količini za prilagodbu pH od 6 do 8, poželjno PH 7,3,
The process of claim 1, wherein the substantially water insoluble polymer particles are added stepwise to the core particles and water soluble and/or swellable material particles during the mixing step. 
Postupak sukladno zahtjevu 1, naznačeno time, da se potpuno u vodi netopive polimerne čestice postepeno dodaju česticama jezgre i u vodi topivim materijalnim česticama, koje bubre u vodi.
a light chain CDR1 having the amino acid sequence of SEQ ID NO: 2, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 3, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 6, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 7, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 8; 
izoliranom protutijelu, ili njegovom antigenski vežućem fragmentu, specifičnom za folatni receptor a (FRa), koje ima CDR1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 2, CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 3, CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 4, CDR1 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 6, CDR2 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 7, te CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 8;
The present invention provides a compound of formula (I): 
Spoj, naznačen time, da ima formulu (I):
The compound of claim 12, wherein the compound is B-6-CH3-(OCH2CH2)6-O-naloxol or a pharmaceutically acceptable salt thereof. 
B-6-CH;-(OCH2CH>);-O-naloksol; ili farmaceutski prihvatljivu sol istih.
The method of claim 4 further comprising a preparation of the compound of formula (4), wherein the method comprises: 
Postupak u skladu s patentnim zahtjevom 4, koji se dodatno sastoji u dobivanju spoja formule (4), naznačen time
from 0.05 to 2.5% by dry weight of an extract of Theobroma species, based on the total weight of the composition. 
- od 0,05 do 2,5% suhe mase ekstrakta vrste Theobroma, na temelju ukupne mase pripravka.
System as claimed in one or more of the foregoing claims, characterized in that the root temperature control means (12) comprise a closed conduit system for receiving therein during operation a liquid flow with a controlled temperature, wherein the conduit system is able and adapted to enter into heat-exchanging contact with the culture substrate. 
Sustav sukladno jednom ili više prethodnih Zahtjeva, naznačen time da sredstva kontrole temperature korijena (12) sadrže zatvoreni sustav kanala za prihvat tekućine kontrolirane temperature, pri čemu je sustav kanala sposoban i prilagođen za izmjenu temperature s supstratom kulture.
The mixing and kneading machine (1) as set forth in claim 3, characterized in that the rotational speed of the screw shaft (3) is adapted to the length of the processing space (6) such that the product residence time in the machine is between 1 and 20 seconds. 
Stroj za miješanje 1 gnječenje(1) sukladno zahtjevu 3 ili 4, naznačen time što je rotacijska brzina osovine (3) prilagođena duljini procesne komore (6) na način da je vrijeme počeka proizvoda u stroju između 1 i 20 sekundi.
Pirfenidone for use in treating a patient according to claim 1, wherein, prior to step (a), said patient is administered pirfenidone at doses lower than 1600 mg/day for a time period. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 1, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 1600 mg/dan u tijeku vremenskog perioda.
The method according to claim 15 characterized in that the mammal is selected from the group consisting of cats, dogs, or horses. 
Uporaba u skladu s patentnim zahtjevom 13, naznačena time, da su sisavci mačke, psi, ili konji.
The data reported are the onset temperature, peak temperature, and enthalpy. 
Podaci koji su zabilježeni su onset temperatura, temperatura pika, te entalpije.
A method as claimed in claim 1, characterized in that the portion separating the sheets (6, 7) to be laminated of the flexible and bending resistant sheet (2, 2") is also bonded to the sheets to be laminated. A method as claimed in claim 1 or 2, characterized in that the method further comprises: 
Postupak kao što je naveden u patentnom zahtjevu 1, naznačen time, što u predjelu gdje su listovi (6, 7) razdvojeni, oni se spajaju preko lista (2, 2") koji je otporan na pregibanje i na savijanje i koji list se također povezuje s listovima na koje treba biti spojen.
Rc is selected from the group consisting of halogen, -CH3 -CF3, and -CN; 
Rc je izabran iz grupe koju čine halogen, -CH3, -CF3 i -CN; q je 2 ili 3; i t je cijeli broj od 0-2.
Refractory ceramic batch composition, use of a batch composition of this type, and metallurgical melting vessel 
VATROSTALNA KERAMIČKA SMJESA, UPORABA TAKVE SMJESE I METALURŠKA POSUDA ZA TALJENJE
Nucleic acid for use according to any one of claims 1 to 13, characterized in that cancer diseases are selected from colon carcinomas, melanomas, renal carcinomas, lymphomas, acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), gastrointestinal tumours, pulmonary carcinomas, gliomas, thyroid tumours, mammary carcinomas, prostate tumours, hepatomas, various virus-induced tumours such as, for example, papilloma virus-induced carcinomas (e.g. 
RNA molekula prema zahtjevu 1 naznačena time da je za uporabu za liječenje kanceroznih bolesti, autoimune bolesti, alergija ili zaraznih bolesti, pri čemu su kancerozne bolesti poželjno odabrane iz skupine koja sadrži karcinom debelog crijeva, melanom, karcinom bubrega, limfom, akutnu mijeloidnu leukemiju (AML), akutnu limfoidnu leukemiju (ALL), kroničnu mijeloidnu leukemiju (CML), kroničnu limfocitnu leukemiju (CLL), gastrointestinalne tumore, karcinome pluća, gliome, tumore štitnjače, karcinome dojke, tumore prostate, hepatome, razne tumore uzrokovane virusima kao što su, na primjer, karcinomi uzrokovani papiloma virusom (npr.
The expandable sheath of claim 1, wherein the outer member is fixedly attached to an outer surface of the inner member at a location around a perimeter of the inner member away from the circumferentially spaced folded portions. 
Navlaka (8) prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što najmanje jedan uzdužno proširivi dio vanjske površine unutarnjeg cjevastog sloja (42) prianja na odgovarajući uzdužno proširivi dio unutarnje površine vanjskog cjevastog sloja (40).
The X-ray crystallography data are set out in Example 4. 
Podaci kristalografije X-zrakama su prikazani u Primjeru 4.
The isolated antibody or fragment thereof of claims 3, 6 or 9, wherein the HER3 ligand is selected from the group consisting of neuregulin 1 (NRG), neuregulin 2, betacellulin, heparin-binding epidermal growth factor, and epiregulin. 
Izolirano protutijelo ili njegov fragment prema zahtjevu 3, 6 ili 9, naznačen/o time, da je HER3-ligand odabran iz skupine koju čine neuregulin 1 (NRG), neuregulin 2, betacelulin, epidermalni faktor rasta koji veže heparin, i epiregulin.
fermenting the aqueous mixture to produce ethanol; 
(ii) fermentiranje vodene smjese da se dobije etanol;
System (1) according to claim 1, characterized in that said heating element (5) is equipped with at least one thermo-regulating element, placed in a distal part of said heating element (5). 
Sustav (1) sukladno patentnom zahtjevu 1, naznačen time što navedeni grijač (5) s najmanje jednim termoregulacijskim elementom, postavljenim na distalnom dijelu grijača (5).
or a pharmaceutically acceptable salt thereof, comprising reacting a compound of formula (VI): 
(D ili odgovarajuće farmaceutski pirihvatljive soli, naznačen time da obuhvaća reakciju spoja formule (VI) x
The present invention further provides a medicament as described above for the treatment and/or prophylaxis of primary and secondary forms of diabetic microangiopathies, diabetic wound healing, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic retinopathy, diabetic nephropathy, diabetic erectile dysfunction, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies. 
Lijek prema zahtjevu 11 ili 12 naznačen time da je za liječenje i/ili profilaksu primarnih 1 sekundarnih oblika dijabetičkih mikroangiopatija, dijabetičkog zacjeljivanja rana, dijabetičkih ulkusa na ekstremitetima, naročito za poticanje zarastanja rana dijabetičkih ulkusa na stopalima, dijabetičke retinopatije, dijabetičke nefropatije, dijabetičke erektilne disfunkcije, dijabetičkog zatajenja srca, dijabetičkih koronarnih mikrovaskularnih poremećaja srca, perifernih 1 srčanih vaskularnih poremećaja, naročito periferne okluzivne bolesti, tromboembolijskih poremećaja 1 ishemija, perifernih poremećaja cirkulacije, Raynaudovog fenomena, CREST sindroma, mikrocirkulacijskih poremećaja, povremene klaudikacije, perifernih i autonomnih neuropatija.
• at least one pushbutton for manual calls 
najmanje jednu tipku za ručne pozive
The process according to claim 15, wherein the aqueous suspension comprising surface-treated natural calcium carbonate is stabilized with a dispersant. The process according to claim 16, wherein the surface-treated natural calcium carbonate is stabilized with a cationic dispersant, and wherein the surface-treated natural calcium carbonate has been prepared from marble in the presence of at least one silicate. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu se površinski-reagirani prirodni kalcij karbonat dodaje u vodu koju treba pročistiti u obliku vodene suspenzije, opcionalno stabilizirane sa disperzantom, posebno kationskim disperzantom, ako je površinski-reagirani prirodni kalcij karbonat pripremljen od mramora u prisutnosti barem jednog silikata.
A second variant to the device according to the present invention is shown in fig. 4 where, much the same as in the first variant, for sake of ease only new numerals are drafted, being the rest of the circuit the same as the one previously described. 
Druga varijanta uređaja prema ovom izumu je prikazana na slici 4, gdje su, slično prethodnoj varijanti, zbog preglednosti izvučene su samo nove oznake, dok je ostatak kruga ostao kao prije.
Furthermore, said mechanically dewatered organic material may according to another aspect of the present invention have a dry solid content of at least 10% by weight, preferably at least 15% by weight, more preferably at least 20% by weight, most preferred 25% by weight. 
Metoda u skladu s patentnim zahtjevom 60, pri čemu navedeni mehanički dehidrirani organski materijal ima suhi kruti sadržaj od najmanje 10 % prema težini, poželjno najmanje 15 % prema težini, poželjnije najmanje 20 % prema težini, najpoželjnije 25 % prema težini.
reacting a compound having the formula: with to form a compound having the formula: and 
reakcije spoja koji ima formulu: s da bi se formirao spoj koji ima formulu:
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein said human malignant cells are cells from a solid tumor. 
Uporaba u skladu s patentnim zahtjevom I ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedene maligne stanice stanice iz solidnog tumora.
a nucleotide sequence which is the reverse complement of a nucleotide sequence as defined in (a), (b), or (c) and said nucleotide encodes a polypeptide according to claim 1. 
(d) nukleotidnu sekvencu koja je reverzni komplement nukleotidne sekvence kako je definirano u (a), (b), ili (c)i navedeni nukleotid kodira polipeptid prema zahtjevu 1.
A nucleic acid molecule encoding the antibody of any one of claims 1 to 11, or a fragment thereof according to claim 12 or 13. 
Molekula nukleinske kiseline, naznačena time što kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegov antigenski vežući fragment u skladu s patentnim zahtjevom 12 ili 13.
The pharmaceutical product of item 3, wherein the matrix comprises a first hydrophobic material. The pharmaceutical product of item 8, wherein the layer comprises a second hydrophobic material. The pharmaceutical product of items 1, 2 or 8, wherein the first hydrophobic material is selected from the group consisting of a cellulosic polymer, acrylic polymer and copolymer, methacrylic acid polymer and copolymers, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, and mixtures of any of the foregoing. 
Farmaceutski proizvod prema zahtjevu 1, naznačen time da su prvi, drugi i treći hidrofobni materijali odabrani iz skupine koja se sastoji od celuloznog polimera, akrilnog polimera i kopolimera, polimera metakrilne kiseline i kopolimera, šelaka, zeina, hidrogeniranog Ticinusovog ulja, hidrogeniranog biljnog ulja, i smjese bilo kojeg prethodno navedenog sa prvim hidrofobnim materijalom i drugim hidrofobnim materijalom koji su poželjno jednaki, sa prvim hidrofobnim materijalom, drugim hidrofobnim materijalom i trećim hidrofobnim materijalom koji su poželjno jednaki, ili sa prvim hidrofobnim materijalom i trećim hidrofobnim materijalom koji su poželjno jdnaki, ili sa drugim hidrofobnim materijalom i trećim hidrofobnim materijalom koji su poželjno jednaki.
The compound of formula I, or a shalt thereof, for use according to claim 4, wherein the autoimmune disease or condition is multiple sclerosis. 
Spoj formule 1, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što autoimuna bolest ili stanje je multipla skleroza.
A process utilizing at least five moles of at least one starting material for preparing an aminoboronic ester compound of formula (VII): or an acid addition salt thereof, wherein: 
Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za pripremu estra amino-organoborne kiseline formule (VII):
Preferably, the core comprises at least one filament which is surrounded by the fibre sheath. 
Poželjno je da jezgra ima barem jednu nit koja je okružena s omotačem od vlakana.
Apparatus according to claim 14, wherein the bottom section of the circulating combustion chamber is frustoconical. 
Uređaj sukladno zahtjevu 16, pri čemu je donji dio (3) cirkulirajuće komore za sagorijevanje (1) oblika krnjeg stošca.
When the composition comprises a nebulised formulation, it preferably contains, e.g., the compound of formula (I) either dissolved, or suspended, in a vehicle containing water, a co-solvent, such as ethanol or propylene glycol and a stabilizer, which may be a surfactant. 
Kad sastav sadrži formulaciju za stvaranje maglice, on sadrži ponajprije, npr. spoj formule (I) otopljen ili suspendiran u vehiklu koji sadrži vođu, ko-otapalo, kao što je etanol ili propilen glikol i stabilizator, koji može biti tenzid.
further optionally, wherein the enucleated nuclear transfer unit cell is an oocyte or an embryonic stem cell. The method of claim 4, further comprising: 
Postupak sukladno patentnom zahtjevu 4 ili 5, naznačena time, da je enukleizirana stanična jedinica nuklearnog prijenosa oocit ili embrionalna matična stanica.
administering an effective amount of a composition containing two components: within the following weight ranges from 1 to 25 mg of a lipophilic extract of Zingiber officinale obtained by extraction with carbon dioxide under supercritical conditions; and 
Upotreba a) lipofilnog ekstrakta Zingiber officinale dobivenog ekstrakcijom s ugljičnim dioksidom pod superkritičnim uvjetima, te b) ekstrakta Cynura scolymus, naznačena time da je za preparaciju prirpavaka za smanjivanje pospanosti nakon obroka.
The general advantages of this aspect of the present invention are, i.a., that ultrasound has a large penetration depth compared normal light curing (UV-curing) used in dentistry, that the packing of the filler particles may be improved, and that curing of the resin base may be conducted while the martensitic transformation of the filler ingredient(s) takes place. 
Opća korist tog aspekta iz ovog izuma je, a to da je ultrazvuk ima veliku mogućnost dubine penetracije u usporedbi s očvršćivanjem uz normalno svjetlo (UV-očvršćivanje) koje se koristi u zubarstvu, da pakiranje čestica za punjenje može biti poboljšano i očvršćivanje baze za smolu se može provesti istovremeno dok se odvija martenzitska transformacija sastoja(aka) za punjenje.
The composition for use of any of claims 1-14, wherein the composition is in the form of a spray. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-10, pri čemu je sastav u obliku raspršivača.
Y is N and R6 is a lone pair of electrons. 
Vje Ni R* je osamljeni par elektrona.
a heavy chain variable region CDR1 of SEQ ID NO: 13; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 41; a light chain variable region CDR1 of SEQ ID NO: 55; a light chain variable region CDR2 of SEQ ID NO: 69; and a light chain variable region CDR3 of SEQ ID NO: 83, or 
(m) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 13; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 27; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 41; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 55; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 69; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 83; ili
In a further example, the invention provides an isolated recombinant antibody, (or a functional protein comprising an antigen binding portion thereof) comprising a full length heavy chain and a full length light chain, wherein: the full length heavy chain comprises an amino acid sequence that is at least 80%, or at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 75-78; the full length light chain comprises an amino acid sequence that is at least 80%, or at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 71-74; the antibody specifically binds to BAFFR, and the antibody exhibits at least one of the following functional properties: it inhibits BLyS induced B cell proliferation, or BLyS induced IgG1 production and it depletes B cell in vitro or in vivo. 
Protutijelo ili funkcionalni protein prema bilo kojem od zahtjeva 1 do 4, naznačen/o time, da obuhvaća jaki lanac pune duljine, koji se sastoji od aminokiselinske sekvence koja je najmanje 95% identična aminokiselinskoj sekvenci odabranoj iz skupine koju čine od SEQ ID NO:75 do SEQ ID NO:78 i slabi lanac pune duljine, koji se sastoji od aminokiselinske sekvence koja je najmanje 95% identična aminokiselinskoj sekvenci odabranoj iz skupine koju čine od SEQ ID NO:71 do SEQ ID NO:74. Protutijelo ili funkcionalni protein prema zahtjevu 5, naznačen/o time, da obuhvaća sljedeće: (a) sekvenca jakog lanca od SEQ ID NO:75 1 sekvenca slabog lanca od SEQ ID NO:71; 1li
The tRNA of claim 5 which is orthogonal and base pairs with a codon that is not normally associated with an amino acid. 
Metoda iz patentnog zahtjeva 14, gdje se ortogonalna tRNK baza spaja sa kodonom koji nije obično povezan sa aminokiselinom.
After dissolving the crude 5-bromo-2-chlorobenzoyl chloride in 530 ml of ethylbenzene, the yellow solution was cooled to −3° C. prior to adding AlCl3 (257 g, 1.93 mol) in ˜30 g portions over 60 min to insure that the temperature did not exceed 10° C. The copious amounts of HCl gas which began to evolve after 60% of the AlCl3 had been added were trapped by passing the gas over a stirred conc. 
Dobijeno ulje je očvrslo u toku kasnijeg pražnjenja. HR P20090113 T3 Poslije otapanja sirovog 5-bromo-2-klorobenzoil klorida u 530 ml etilbenzola, žuta otopina je hlađena do -3"C prije dodavanja AlICI; (257 g, 1.93 mol) u dijelove od -30 g u toku 60 min. da bi osiguralo da temperatura ne pređe 10C.
After the mass has been deposited in the moulds, the moulds are stacked and transferred to drying ovens. 
Nakon što je masa postavljena u kalupe, kalupi su naslagani i prebačeni u peći za sušenje.
The compound according to claim 3 wherein R1 is OH, methyl, ethyl, methoxy, ethoxy, methylcarboxy, Cl, Br, F or cyano. 
Tvar u skladu s patentnim zahtjevom 3 pri čemu je R1 OH, metil, etil, metoksi, etoksi, metilkarboksi, CI, Br, F ili cijano.
Test have shown that not only the inhaler (GSK product) keeps all its advantages (bridging of powder avoided, minimum of powder waste, maximum of useful life of device, accurate delivery of less flowable powders thus allowing the use of powder blends with reduced course excipient to drug ratios, hormone metered being constant regardless the number the auger is rotated after the appropriate dose has been metered, even dosing etc.) 
Ispitivanja su pokazala da ne samo inhalator (proizvod GSK) zadržava sve prednosti (izbjegnuto premošćivanje praha, minimalni gubitak praha, maksimum korisnog života uređaja, točna dostava manje tečnih prahova što omogućava upotrebu mješavina prahova sa smanjenim omjerom pomoćne tvari prema lijeku u terapiji, konstantno odmjeravanje hormona bez obzira na broj okretaja svrdla nakon što je odmjerena prikladna doza, jednako doziranje itd.
HfO2 nanoparticles or nanoparticles' aggregates for use for altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein the density of said HfO2 nanoparticles or the density of said HfO2 nanoparticles' aggregates is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Nanočestice HfO2 ili agregati nanočestica za uporabu pri mijenjanju ili uništavanju ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO2 ili gustoća spomenutih agregata nanočestica HfO2 barem 7 g/cm3, i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 i 7,5 u fiziološkoj tekućini.
A method for making a lyophilized KGF composition according to claim 1 comprising the steps of preparing a solution of KGF in a concentration between 3 mg/mL and 15 mg/mL; the buffer histidine; mannitol at a concentration of 2% to 5% w/v; sucrose at a concentration of 1% to 3% w/v; polysorbate 20 at a concentration within a range of 0.004% to 0.1% w/v, wherein the pH is in a range of 6.0 to 8.0; and 
Postupak za pripremu liofilizirane KGF kompozicije prema patentnom zahtjevu 1 koji sadrži korake a) pripreme otopine KGF u koncentraciji između 3 mg/mL i 15 mg/mL; histidina kao pufera; manitola u koncentraciji od 2% do 5% tež./vol.; saharoze u koncentraciji od 1% do 3% tež./voL; polisorbata 20 u koncentraciji unutar opsega od 0.004% do 0.1% tež./vol., pri čemu je pH u opsegu od 6.0 do 8.0; 1 b) liofilizacije navedene otopine KGF da bi se dobila navedena liofilizirana kompozicija KGF.